U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H10O5
Molecular Weight 270.2369
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BAICALEIN

SMILES

OC1=CC2=C(C(=O)C=C(O2)C3=CC=CC=C3)C(O)=C1O

InChI

InChIKey=FXNFHKRTJBSTCS-UHFFFAOYSA-N
InChI=1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H

HIDE SMILES / InChI

Molecular Formula C15H10O5
Molecular Weight 270.2369
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Baicalein is a flavonoid is a component of the traditional herbal remedy known as Chinese skullcap (or Huang Qin), possesses various biological activities. Baicalein is a neuroprotective agent, which is studied in phase I for the treatment of Parkinson’s disease. By modulating of γ-aminobutyric acid (GABA) type A receptors, baicalein promotes nonamyloidogenic processing of amyloid precursor protein (APP), thereby reducing β-amyloid (Aβ) production and improving cognitive performance in models of Alzheimer's disease. By inhibiting the NF-κB signaling pathway, baicalein suppressed cancer cells proliferation and suppressed the viability of human endometrial stromal cells, thus it may provide a novel treatment option for endometriosis. Besides, this compound was evaluated for its ability to inhibit the influenza virus. Experiments on mice have shown that baicalein showed significant effects in preventing death, increasing the mean time to death and reducing the lung virus titer in a dose-dependent manner.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
13.1 µM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
65.171 ng/mL
800 mg 2 times / day steady-state, oral
BAICALEIN plasma
Homo sapiens
1322.5 ng/mL
600 mg 3 times / day steady-state, oral
BAICALEIN plasma
Homo sapiens
17.61 ng/mL
200 mg 2 times / day steady-state, oral
BAICALEIN plasma
Homo sapiens
31.723 ng/mL
400 mg 2 times / day steady-state, oral
BAICALEIN plasma
Homo sapiens
1508.45 ng/mL
600 mg 3 times / day steady-state, oral
BAICALIN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
598.4 ng × h/mL
800 mg 2 times / day steady-state, oral
BAICALEIN plasma
Homo sapiens
12580.06 ng × h/mL
600 mg 3 times / day steady-state, oral
BAICALEIN plasma
Homo sapiens
169 ng × h/mL
200 mg 2 times / day steady-state, oral
BAICALEIN plasma
Homo sapiens
332.9 ng × h/mL
400 mg 2 times / day steady-state, oral
BAICALEIN plasma
Homo sapiens
10175.14 ng × h/mL
600 mg 3 times / day steady-state, oral
BAICALIN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
11.09 h
800 mg 2 times / day steady-state, oral
BAICALEIN plasma
Homo sapiens
8.8 h
200 mg 2 times / day steady-state, oral
BAICALEIN plasma
Homo sapiens
12.53 h
400 mg 2 times / day steady-state, oral
BAICALEIN plasma
Homo sapiens

PubMed

Sample Use Guides

In Vivo Use Guide
Phase I, randomized, double-blind, single-dose trial of baicalein (100-2800 mg) in 72 healthy adults. These doses were safe and well tolerated by healthy subjects.
Route of Administration: Oral
In Vitro Use Guide
Baicalein (200 µM) was used to treat human cervical cancer cell line C33A cells. Cell proliferation was tested by the MTT assay. Cell apoptosis was detected by the TUNEL assay and caspase 3 activity measurement. Baicalein inhibited NF κB activity by repressing nuclear translocation. Baicalein suppressed C33A proliferation and promoted cellular apoptosis by inhibiting NF κB signaling pathway.
Substance Class Chemical
Record UNII
49QAH60606
Record Status Validated (UNII)
Record Version